Cellectis S.A. - American Depositary Shares (CLLS)
3.4200
+0.00 (0.00%)
NASDAQ · Last Trade: Oct 3rd, 9:07 AM EDT
Before the opening bell on Monday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session.
Via Chartmill · September 29, 2025
Gainers Dogwood Therapeutics (NASDAQ: DWTX) stock moved upwards by 80.1% to $9.94 during Monday's pre-market session. The market value of their outstanding shares is at $10.5 million.
Via Benzinga · September 29, 2025
U.S. stock futures were higher this morning, with the Dow futures gaining more than 100 points on Monday. Shares of Inventiva ADR (NASDAQ: IVA) fell sharply in today's pre-market trading following H1 results.
Via Benzinga · September 29, 2025

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earnings at $0.16 per share on revenue of $366.82 million.
Via Benzinga · November 6, 2023
Shares of Merus NV (NASDAQ: MRUS) rose sharply in today's pre-market trading. Genmab announced plans to acquire Merus for $8 billion in all-cash deal adding breakthrough therapy Petosemtamab to its late-stage pipeline.
Via Benzinga · September 29, 2025
Via Benzinga · September 19, 2025
Top 5 biotech stocks jumping into the top 10% momentum this week—ADCT, ARQT, CLLS, ENTO, HOTH—amid rapid sector rallies.
Via Benzinga · August 28, 2025
Via Benzinga · July 29, 2025
Here are the top movers in Friday's session, showcasing the stocks with significant price changes.
Via Chartmill · July 25, 2025
Cellectis, backed by AstraZeneca funding and a multi-year cash runway, is advancing its prioritized allogeneic CAR-T pipeline toward pivotal 2025 milestones.
Via MarketBeat · April 22, 2025
Today's session on Friday is marked by notable gaps in various stocks. Stay informed with the gap up and gap down stocks in today's session.
Via Chartmill · April 11, 2025
Via Benzinga · March 14, 2025
Via Benzinga · March 14, 2025
Via Benzinga · March 14, 2025

CLLS stock results show that Cellectis beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024.
Via InvestorPlace · August 6, 2024

CLLS stock results show that Cellectis beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via InvestorPlace · May 28, 2024

CLLS stock results show that Cellectis missed analyst estimates for earnings per share and missed on revenue for the fourth quarter of 2023.
Via InvestorPlace · April 29, 2024

Gainers OmniLit Acquisition Corp. (NASDAQ: OLIT) jumped 53.2% to $15.53. OmniLit announced that its merger with Syntec was approved by shareholders.
Via Benzinga · November 2, 2023